Why universal gene synthesis screening protects American biotech
In an era when Washington seems incapable of finding common ground on virtually any issue, it’s notable to encounter a policy area where stakeholders across the political spectrum agree. Gene synthesis screening has emerged as one of those increasingly rare issues with genuine bipartisan momentum, where economic and security interests and industry expertise all point in the same direction. A recent bipartisan bill, the Biosecurity Modernization and Innovation Act, outlines an ambitious vision for comprehensive gene synthesis screening standards. To understand why this matters, we need to start with the technology itself.
